Clinical Trials Directory

Trials / Completed

CompletedNCT06564259

Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients

The Relationship Between Serum Beta-2 Microglobulin (sB2M) Levels and CD8+ Cell Infiltration in Hodgkin Lymphoma Tissues: Impact on Chemotherapy Outcomes

Status
Completed
Phase
Study type
Observational
Enrollment
144 (actual)
Sponsor
Tishreen University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samples will be collected for Immunohistochemical (IHC) analysis to quantify CD8+ cell infiltration. Patients will be closely monitored throughout their treatment, with a follow-up CT scan at the end of therapy to evaluate therapeutic response. This study aims to investigate the correlation between pre-treatment B2M levels and CD8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.

Conditions

Timeline

Start date
2024-01-04
Primary completion
2024-08-15
Completion
2024-08-15
First posted
2024-08-21
Last updated
2024-08-21

Locations

1 site across 1 country: Syria

Source: ClinicalTrials.gov record NCT06564259. Inclusion in this directory is not an endorsement.

Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients (NCT06564259) · Clinical Trials Directory